Roche’s BTK inhibitor fenebrutinib significantly reduced brain lesions in people with relapsing forms of multiple sclerosis
May 17, 2023 01:00 ET
|
F. Hoffmann-La Roche Ltd
Fenebrutinib is an investigational, potent and highly selective oral Bruton’s tyrosine kinase (BTK) inhibitor, the only reversible BTK inhibitor currently in Phase III multiple sclerosis (MS)...
FDA accepts application for Roche’s Vabysmo for the treatment of retinal vein occlusion (RVO)
May 09, 2023 01:00 ET
|
F. Hoffmann-La Roche Ltd
Acceptance based on two phase III studies that demonstrated early and sustained vision improvement with Vabysmo, meeting primary endpoint of non-inferiority compared to afliberceptApplication was...
Roche launches Institute of Human Biology to accelerate breakthroughs in R&D by unlocking the potential of human model systems
May 04, 2023 01:00 ET
|
F. Hoffmann-La Roche Ltd
The Institute of Human Biology aims to better predict which drug candidates are safe and most effective in patients by evolving and increasing the use of human model systems. Human model systems are...
CHMP recommends EU approval of Roche’s fixed-duration Columvi (glofitamab) for people with relapsed or refractory diffuse large B-cell lymphoma
April 26, 2023 12:50 ET
|
F. Hoffmann-La Roche Ltd
Once approved, Columvi will be the first CD20xCD3 T-cell-engaging bispecific antibody available to treat people in Europe with this aggressive lymphomaThe recommendation is based on results from the...
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong sales growth in base business of both divisions in the first quarter; Group sales decline due to expected drop in demand for COVID-19 tests
April 26, 2023 01:00 ET
|
F. Hoffmann-La Roche Ltd
Basel, 26 April 2023 As expected, significantly lower demand for COVID-19 tests leads to a decrease in Group sales (-3%1 at constant exchange rates [CER] and -7% in Swiss francs); excluding this...
[Annonce événementielle selon l’art. 53 RC] Roche annonce une forte croissance des ventes dans les activités de base de ses deux divisions au T1 ; le recul des ventes du Groupe est dû à la baisse attendue de la demande de tests COVID-19
April 26, 2023 01:00 ET
|
F. Hoffmann-La Roche Ltd
Bâle, le 26 avril 2023 Comme attendu, la baisse significative de la demande de tests COVID-19 entraîne une diminution des ventes du Groupe (-3 %1 à taux de change constants [TCC] et -7 % en francs...
[Ad-hoc-Mitteilung gemäss Art. 53 LR] Roche erzielt im ersten Quartal ein starkes Verkaufswachstum im Basisgeschäft beider Divisionen; Rückgang der Konzernverkäufe aufgrund der erwartungsgemäss geringeren Nachfrage nach COVID-19-Tests
April 26, 2023 01:00 ET
|
F. Hoffmann-La Roche Ltd
Basel, 26. April 2023 Wie erwartet führt die stark rückläufige Nachfrage nach COVID-19-Tests zu einer Abnahme der Konzernverkäufe (-3%1 zu konstanten Wechselkursen [CER] und -7% in Schweizer...
New Vabysmo data suggest greater retinal drying versus aflibercept in nAMD and DME
April 25, 2023 15:00 ET
|
F. Hoffmann-La Roche Ltd
Post-hoc analyses from four phase III studies indicate Vabysmo dried retinal fluid faster with fewer injections in neovascular or ‘wet’ age-related macular degeneration (nAMD) and diabetic macular...
[Ad hoc announcement pursuant to Art. 53 LR] FDA approves Roche’s Polivy in combination with R-CHP for people with certain types of previously untreated diffuse large B-cell lymphoma
April 19, 2023 15:30 ET
|
F. Hoffmann-La Roche Ltd
Polivy combination is the first FDA-approved therapy in nearly 20 years for the first-line treatment of diffuse large B-cell lymphoma, an aggressive disease and the most common form of non-Hodgkin...
Roche’s Tecentriq plus Avastin reduced the risk of cancer returning in people with certain types of adjuvant liver cancer in a Phase III study
April 16, 2023 11:00 ET
|
F. Hoffmann-La Roche Ltd
In the first-ever positive Phase III trial in the adjuvant hepatocellular carcinoma (HCC) setting, Tecentriq plus Avastin reduced the risk of disease recurrence by 28%1Up to 80% of people with this...